Shares of Arcus Biosciences Inc (NYSE:RCUS) have been given an average rating of “Buy” by the six research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $19.00.
RCUS has been the subject of several research reports. Mizuho initiated coverage on shares of Arcus Biosciences in a research report on Thursday, September 26th. They issued a “buy” rating and a $22.00 price target for the company. Zacks Investment Research cut shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Finally, ValuEngine raised shares of Arcus Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Arcus Biosciences stock traded up $0.03 during trading hours on Tuesday, hitting $8.44. The company had a trading volume of 175,057 shares, compared to its average volume of 362,113. The firm has a market cap of $385.59 million, a P/E ratio of -5.90 and a beta of 1.04. Arcus Biosciences has a 1 year low of $6.30 and a 1 year high of $13.77. The company has a 50-day moving average price of $8.52 and a two-hundred day moving average price of $8.98.
Institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in shares of Arcus Biosciences by 17.3% during the 2nd quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock worth $129,000 after acquiring an additional 2,392 shares in the last quarter. Aperio Group LLC bought a new position in shares of Arcus Biosciences during the 2nd quarter worth approximately $32,000. Meeder Asset Management Inc. raised its stake in shares of Arcus Biosciences by 672.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock worth $46,000 after acquiring an additional 4,300 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Arcus Biosciences by 9.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 116,983 shares of the company’s stock worth $930,000 after acquiring an additional 9,980 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of Arcus Biosciences during the 2nd quarter worth approximately $119,000. 46.66% of the stock is owned by hedge funds and other institutional investors.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Article: How to identify percentage decliners
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.